DOCUMENTS

papers

Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study

Published: April 2, 2015
Category: Bibliography > Papers
Authors: Campitelli MA, De P, Earle CC, Khoo E, Thein HH, Yi Q, Zaheen A
Countries: Canada
Language: null
Types: Care Management
Settings: Academic, Hospital

CMAJ Open 3:E208-E216.

University of Toronto, Toronto, ON, Canada; Ontario Institute for Cancer Research/Cancer Care Ontario, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, ON, Canada; Canadian Cancer Society, Toronto, ON, Canada

BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is increasing and survival rates are poor. Our objectives were to estimate the relative survival over time in patients with HCC in Ontario and to examine potential factors associated with excess mortality risk.

METHODS: We performed a population-based retrospective cohort analysis involving patients with a diagnosis of HCC in Ontario between 1990 and 2009 using data extracted from the Ontario Cancer Registry. Relative survival was estimated by controlling for background mortality using expected mortality from Ontario life tables. A generalized linear model was used to estimate the excess mortality risk for important factors.

RESULTS: A total of 5645 patients had HCC diagnosed during the study period; 4412 (78.2%) of these patients were male. Improvements in 1-year relative survival were observed across all age groups over time: the highest was among those patients aged 60 years or younger who had a diagnosis of HCC during 2005-2009, with 1-year relative survival exceeding 50% for both sexes. However, the overall 5-year relative survival did not exceed 28%. The excess mortality risk decreased with increased years of follow-up, recent diagnosis, and curative or noncurative treatments for HCC, whereas excess mortality risk increased with age.

INTERPRETATION: Although improving, the prognosis for HCC remains poor. Our findings highlight the importance of effective prevention and treatment for HCC to reduce the burden of disease and improve health care systems.

PMID: 26389099
PMCID: PMC4565177

Canada,Medical Conditions,Mortality Prediction,High Risk,Gender

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top